Some indicators suggest that equity markets are currently overvalued. For instance, the S&P 500 Shiller CAPE ratio is near multi-year highs. In this environment, it pays to look for bargains, stocks that look cheap right now, given their growth prospects. Here are two examples to consider in the healthcare sector: Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO). Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, calle ...

Core Insights - The article highlights the growing impact of artificial intelligence (AI) across various industries, particularly in healthcare, with a focus on Pfizer and Eli Lilly as attractive investment opportunities due to their AI initiatives. Group 1: Pfizer - Pfizer has been utilizing AI since before the significant industry shift marked by the launch of ChatGPT in late 2022, notably in the development of its coronavirus vaccine, Comirnaty, in collaboration with BioNTech [4]. - The company is expanding its AI applications in drug discovery, commercial efforts, and manufacturing optimization to enhance efficiency and speed up the time to market for new compounds [5]. - Despite recent challenges, including declining sales from Comirnaty and upcoming patent cliffs for key products like Eliquis, Pfizer is making clinical progress with promising candidates entering phase 3 studies, such as MET-097i for weight loss and PF'4404 for cancer [6][7]. - While AI efforts may not lead to immediate business transformation, they have already contributed to significant cost reductions, and ongoing improvements in research and development could yield long-term benefits, making the stock appealing given its recent underperformance [8]. Group 2: Eli Lilly - Eli Lilly has recently constructed the most powerful supercomputer in the pharmaceutical industry with Nvidia's assistance, aimed at enhancing its capacity for novel medicine development [9]. - The company has established an AI innovation lab where its scientists collaborate with Nvidia's engineers to refine the drug discovery and development process [9]. - Eli Lilly's AI initiatives are viewed as supplementary to its already strong growth potential, positioning it as one of the top growth stocks in the healthcare sector [9].

Core Viewpoint - Pfizer has faced disappointing financial results, leading to a decline in stock price, with concerns about revenue direction and modest growth in adjusted earnings per share (EPS) for 2025 and weak guidance for 2026 [1] Group 1: Financial Performance - Pfizer's stock price dropped approximately 4% following its latest quarterly update, reflecting market concerns about its financial trajectory [1] - The company has seen a significant decline in shares over the past three years, with challenges expected due to key patent cliffs, particularly for its anticoagulant Eliquis [4] Group 2: Future Opportunities - Despite current setbacks, there are reasons to consider investing in Pfizer, as the pharmaceutical market often rewards companies during clinical development phases [2] - Pfizer anticipates progress in 20 pivotal clinical trials this year, including 10 for weight management assets from its Metsera acquisition and four for the investigational cancer medicine PF'4404, which could lead to significant stock price increases if results are positive [5] Group 3: Market Dynamics - The market tends to price in potential blockbuster drugs only after they are launched, suggesting that there may be substantial upside as late-stage clinical trial successes occur [3] - The uncertainty surrounding clinical trial outcomes creates both risk and opportunity, as positive results could lead to significant stock appreciation before the drugs generate substantial sales [6]

Core Insights - Pfizer reported strong Q4 2025 earnings with revenue of $17.6 billion, aligning closely with previous expectations of $18.1 billion, and adjusted net income of $3.8 billion, exceeding the prior forecast of $3.3 billion [2] - Total revenue for 2025 is projected at $62.6 billion, a 2% year-over-year decline, but operational revenue excluding COVID-19 products grew by 6%, indicating robust underlying business momentum [2] - The management reaffirmed guidance for 2026, expecting revenue between $59.5 billion and $62.5 billion, with adjusted EPS ranging from $2.80 to $3.00, highlighting a year rich in catalysts [2] Company Analysis - Pfizer's pipeline includes significant catalysts such as long-acting GLP-1 and Amylin projects, with key data readouts expected in 2026 [2] - The VESPER-3 study demonstrated a 12.3% weight loss effect at the 28-week mark for the mid-dose group of PF'3944, with predictions suggesting a 15.8% weight loss for the high-dose group [6] - The company plans to initiate a Phase 3 study for PF'3944 later this year, with further updates on its obesity product portfolio expected [6][7] Market Performance - The Hang Seng Index closed at 26,847, reflecting a slight increase of 0.05% for the day and a year-to-date gain of 4.75% [2] - The U.S. stock market saw declines, particularly in technology and consumer discretionary sectors, while energy and materials sectors showed strength [4] - Notable movements included a 17% drop in AMD shares following weak guidance, impacting the semiconductor sector [4]

Investment Rating - The report maintains a "Buy" rating for Pfizer Inc. (PFE US) with a target price of $35.46, down from the previous target of $36.16, reflecting a potential upside of 32.4% from the current price of $26.78 [5][7]. Core Insights - Pfizer reported strong Q4 2025 results with revenues of $17.6 billion, aligning closely with the forecast of $18 billion. Adjusted net income was $3.8 billion, exceeding the estimate of $3.3 billion. Excluding COVID-19 products, operational revenue grew by 6% year-over-year, indicating a robust business foundation [3]. - The management reiterated revenue guidance for 2026 at $59.5 billion to $62.5 billion, with adjusted EPS projected between $2.80 and $3.00. Anticipated catalysts for 2026 include key data releases for long-acting GLP-1 and insulin projects, as well as positive clinical progress for obesity products and PF'4404 [3][5]. - The VESPER-3 study results for PF'3944 showed a 12.3% weight reduction at the medium dose, with expectations for the high dose to achieve a 15.8% reduction, positioning it competitively against alternatives [4]. - Pfizer is rapidly advancing the integration of PF'4404 (PD-1/VEGF) with its leading ADC product portfolio, aiming to establish a dominant position in the oncology market [5]. Financial Summary - For FY2026, revenue is projected at $60.7 billion, with a year-over-year decline of 2.9%. Adjusted net income is expected to be $16.34 billion, reflecting an 8.8% decrease from the previous year [6][16]. - The report outlines a decrease in P/E ratios, with FY2026 expected at 14.1x, down from 19.6x in FY2024, indicating a shift in valuation metrics [6][17]. - The DCF valuation estimates a share value of $35.46, based on a WACC of 9.95% and a terminal growth rate of 2.0% [13][14].

Market Performance - The Hang Seng Index closed at 26,847, with a slight increase of 0.05% for the day and a year-to-date increase of 4.75% [1] - The Hang Seng Technology Index decreased by 1.84% for the day and is down 2.71% year-to-date [1] - The US stock market saw the Dow Jones increase by 0.53%, while the S&P 500 and Nasdaq fell by 0.51% and 1.51%, respectively [1] Sector Performance - In the Hong Kong market, the financial sector increased by 0.66% and is up 8.51% year-to-date, while the industrial sector decreased by 0.48% [2] - The real estate sector in Hong Kong saw a significant increase of 1.99% for the day and is up 17.13% year-to-date [2] Capital Flows - Southbound funds recorded a net inflow of 13.373 billion HKD, with Tencent, Alibaba, and Xiaomi being the top net buyers [3] - In contrast, SMIC, Hua Hong Semiconductor, and Jun Da Co. were the most sold stocks [3] US Market Trends - The US stock market experienced a sell-off in technology stocks, particularly in software and semiconductor sectors, with AMD's weak guidance leading to a 17% drop [3] - The S&P 500 software sector has seen an average decline of 25% since reaching a historical high last October [3] Company Analysis: Pfizer (PFE US) - Pfizer reported strong Q4 2025 earnings with revenue of 17.6 billion USD, slightly below the expected 18.1 billion USD, but adjusted net income exceeded expectations at 3.8 billion USD [4] - The company anticipates 2026 revenue between 59.5 billion to 62.5 billion USD, with adjusted EPS guidance of 2.80 to 3.00 USD [4] - Key upcoming milestones include data readouts for long-acting GLP-1 and Amylin projects, which are expected to drive significant valuation re-evaluation [4] Clinical Developments - Pfizer's VESPER-3 study showed a 12.3% weight loss effect at the 28-week mark for its long-acting GLP-1 candidate, with a potential 15.8% weight loss projected for a higher dose [5] - The company plans to initiate a Phase 3 study for the higher dose later this year, with detailed data expected at the ADA conference in June [5] Oncology Pipeline - Pfizer is advancing its PD-1/VEGF and ADC combination therapies, with ongoing Phase 3 trials for PF'4404 in colorectal cancer and additional trials planned for 2026 [6] - The market narrative is shifting towards pipeline execution strength, with obesity products and PF'4404 clinical progress expected to drive stock price increases [6]